Basilea reports at ESMO meeting that drug candidate derazantinib showed clinical benefit in intrahepatic cholangiocarcinoma (iCCA) patients with various FGFR2 genetic aberrations

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing